- Home
- SCLX vs CLPS Comparison
SCLX vs CLPS Comparison
Compare SCLX & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- CLPS
- Stock Information
- Founded
- SCLX 2011
- CLPS 2005
- Country
- SCLX United States
- CLPS Hong Kong
- Employees
- SCLX N/A
- CLPS N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- SCLX Health Care
- CLPS Technology
- Exchange
- SCLX Nasdaq
- CLPS Nasdaq
- Market Cap
- SCLX 35.7M
- CLPS 29.7M
- IPO Year
- SCLX N/A
- CLPS 2018
- Fundamental
- Price
- SCLX $16.46
- CLPS $0.94
- Analyst Decision
- SCLX Buy
- CLPS
- Analyst Count
- SCLX 2
- CLPS 0
- Target Price
- SCLX $245.00
- CLPS N/A
- AVG Volume (30 Days)
- SCLX 255.7K
- CLPS 286.6K
- Earning Date
- SCLX 08-13-2025
- CLPS 10-17-2025
- Dividend Yield
- SCLX N/A
- CLPS 13.54%
- EPS Growth
- SCLX N/A
- CLPS N/A
- EPS
- SCLX N/A
- CLPS N/A
- Revenue
- SCLX $44,236,000.00
- CLPS $164,481,414.00
- Revenue This Year
- SCLX $89.26
- CLPS N/A
- Revenue Next Year
- SCLX $203.95
- CLPS N/A
- P/E Ratio
- SCLX N/A
- CLPS N/A
- Revenue Growth
- SCLX N/A
- CLPS 15.17
- 52 Week Low
- SCLX $3.60
- CLPS $0.80
- 52 Week High
- SCLX $39.90
- CLPS $1.88
- Technical
- Relative Strength Index (RSI)
- SCLX 47.62
- CLPS 43.27
- Support Level
- SCLX $13.08
- CLPS $0.89
- Resistance Level
- SCLX $14.74
- CLPS $1.88
- Average True Range (ATR)
- SCLX 1.51
- CLPS 0.14
- MACD
- SCLX -0.07
- CLPS -0.03
- Stochastic Oscillator
- SCLX 55.24
- CLPS 0.67
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.